<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01822977</url>
  </required_header>
  <id_info>
    <org_study_id>13-000180</org_study_id>
    <nct_id>NCT01822977</nct_id>
  </id_info>
  <brief_title>The Impact of Proton Pump Inhibitors on the Fecal Microbiome</brief_title>
  <official_title>The Impact of Proton Pump Inhibitors on the Fecal Microbiome and Their Relationship to Clostridium Difficile Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesis is that daily use of a proton pump inhibitor (PPI) is associated&#xD;
      with significant alterations in the healthy fecal microbiome that are similar to those seen&#xD;
      in persons with an initial episode of clostridium difficile infection (CDI).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in fecal microbial diversity due to PPI therapy</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in fecal microbial diversity due to CDI</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Healthy</condition>
  <condition>Clostridium Difficile Infection</condition>
  <arm_group>
    <arm_group_label>Proton pump inhibitor</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>We will recruit 10 healthy adult individuals and 5 adult patients with an initial episode of CDI cared for at Mayo Clinic in Arizona. A baseline stool sample will be collected from the healthy individuals. They will then be given a PPI, omeprazole 20 mg, to be taken once (n=5) or twice (n=5) daily for 1 month. Stool samples will be collected after 1 week and again after 1 month. A final stool sample will be collected 1 month after stopping the omeprazole.&#xD;
A stool sample will be collected from the CDI subjects before treatment of the infection and again 2 months after treatment to avoid enrolling those at risk for relapse (which most commonly occurs during the first 2 months after treatment).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omeprazole</intervention_name>
    <arm_group_label>Proton pump inhibitor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Table 1. Inclusion Criteria for Healthy Volunteers:&#xD;
&#xD;
        1. Healthy individuals without chronic gastrointestinal problems or using antisecretory&#xD;
        medications.&#xD;
&#xD;
        Table 2. Inclusion Criteria for Clostridium difficile infection subjects:&#xD;
&#xD;
        1. Newly diagnosed first episode of CDI prior to being treated.&#xD;
&#xD;
        Table 3. Exclusion Criteria for Healthy Subjects:&#xD;
&#xD;
          1. Prior gastrointestinal surgery that has altered the anatomy of the esophagus, stomach,&#xD;
             or small/large intestine including appendectomy and cholecystectomy.&#xD;
&#xD;
          2. Chronic daily use of any medications that could alter gastrointestinal secretory or&#xD;
             motor function (see Table 2).&#xD;
&#xD;
          3. Gastrointestinal, cardiovascular, endocrine, renal, or other chronic disease likely to&#xD;
             affect gastrointestinal motility (e.g., uncontrolled diabetes mellitus).&#xD;
&#xD;
          4. Females of childbearing age who are not practicing at least one form of birth control&#xD;
             at least one month prior to starting the PPI or are pregnant or lactating (a pregnancy&#xD;
             test will be performed on female subjects prior to PPI use).&#xD;
&#xD;
          5. Significant untreated psychiatric disease.&#xD;
&#xD;
        Table 4. Prohibited Medications:&#xD;
&#xD;
          1. Antibiotics within 2 months of the stool sample collection.&#xD;
&#xD;
          2. Probiotics (e.g., Florastor, Align, Flora-Q, VSL#3, lactobacillus, bifidobacterium)&#xD;
             within 2 weeks of the stool sample collection.&#xD;
&#xD;
          3. Fiber supplements (e.g., Metamucil, Citrucel, Benefiber), unless maintained on a&#xD;
             stable dose for the last 3 months.&#xD;
&#xD;
          4. Chronic use of medications that alter gastric pH: proton pump inhibitors (e.g.,&#xD;
             omeprazole, lansoprazole, esomeprazole, pantoprazole, rabeprazole, dexlansoprazole)&#xD;
             and histamine2 receptor antagonists (e.g., cimetidine, famotidine, ranitidine).&#xD;
&#xD;
          5. Chronic use of medications that affect gastrointestinal motility and/or transit&#xD;
             including prokinetic agents (e.g., metoclopramide (Reglan), tegaserod (Zelnorm),&#xD;
             domperidone (Motilium), erythromycin), narcotic analgesic agents (e.g., methadone,&#xD;
             fentanyl, oxycodone, codeine, morphine, hydromorphone), laxatives including mineral&#xD;
             oil, anticholinergic agents (e.g., Bentyl, Levsin), and antidiarrheal agents (e.g.,&#xD;
             Kaopectate (donnagel), Pepto-Bismol (bismuth subsalicylate), Imodium (loperamide),&#xD;
             Lomotil (atropine with diphenoxylate), codeine, tincture of opium).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Di Baise, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>March 26, 2013</study_first_submitted>
  <study_first_submitted_qc>April 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2013</study_first_posted>
  <last_update_submitted>August 18, 2014</last_update_submitted>
  <last_update_submitted_qc>August 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>John K. DiBaise</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>gut microbiota</keyword>
  <keyword>proton pump inhibitor</keyword>
  <keyword>Clostridium difficile infection</keyword>
  <keyword>Fecal microbiome</keyword>
  <keyword>single episode of CDI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Clostridium Infections</mesh_term>
    <mesh_term>Enterocolitis, Pseudomembranous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

